150 related articles for article (PubMed ID: 35147017)
1. Female sexual dysfunctions: an overview on the available therapeutic interventions.
da Silva Lara LA; Rufino AC; Oliveira FF; Rossato S; Borges CS; Reis RM
Minerva Obstet Gynecol; 2022 Jun; 74(3):249-260. PubMed ID: 35147017
[TBL] [Abstract][Full Text] [Related]
2. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
[TBL] [Abstract][Full Text] [Related]
3. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
Simon JA; Derogatis L; Portman D; Brown L; Yuan J; Kissling R
J Sex Med; 2018 Mar; 15(3):387-395. PubMed ID: 29502984
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies.
McCool ME; Zuelke A; Theurich MA; Knuettel H; Ricci C; Apfelbacher C
Sex Med Rev; 2016 Jul; 4(3):197-212. PubMed ID: 27871953
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
Derogatis LR; Komer L; Katz M; Moreau M; Kimura T; Garcia M; Wunderlich G; Pyke R;
J Sex Med; 2012 Apr; 9(4):1074-85. PubMed ID: 22248038
[TBL] [Abstract][Full Text] [Related]
7. Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.
Simon JA; Thorp J; Millheiser L
J Womens Health (Larchmt); 2019 Jun; 28(6):769-777. PubMed ID: 30707049
[No Abstract] [Full Text] [Related]
8. Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome.
Alvisi S; Baldassarre M; Lambertini M; Martelli V; Berra M; Moscatiello S; Marchesini G; Venturoli S; Meriggiola MC
J Sex Med; 2014 Aug; 11(8):2020-8. PubMed ID: 24848980
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of sexual dysfunctions and sexually related distress in young women: a cross-sectional survey.
Zheng J; Skiba MA; Bell RJ; Islam RM; Davis SR
Fertil Steril; 2020 Feb; 113(2):426-434. PubMed ID: 32106994
[TBL] [Abstract][Full Text] [Related]
10. Medical Treatment of Female Sexual Dysfunction.
Nappi RE; Tiranini L; Martini E; Bosoni D; Righi A; Cucinella L
Urol Clin North Am; 2022 May; 49(2):299-307. PubMed ID: 35428435
[TBL] [Abstract][Full Text] [Related]
11. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder.
Derogatis L; Clayton A; Lewis-D'Agostino D; Wunderlich G; Fu Y
J Sex Med; 2008 Feb; 5(2):357-64. PubMed ID: 18042215
[TBL] [Abstract][Full Text] [Related]
12. The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD.
Parish SJ; Cottler-Casanova S; Clayton AH; McCabe MP; Coleman E; Reed GM
Sex Med Rev; 2021 Jan; 9(1):36-56. PubMed ID: 32800563
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?
Nappi RE; Tiranini L; Cucinella L; Martini E; Bosoni D; Righi A; Cassani C; Gardella B
Expert Opin Pharmacother; 2023 Jan; 24(1):135-143. PubMed ID: 35430926
[TBL] [Abstract][Full Text] [Related]
14. What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact?
Hayes RD; Dennerstein L; Bennett CM; Fairley CK
J Sex Med; 2008 Apr; 5(4):777-787. PubMed ID: 18266650
[TBL] [Abstract][Full Text] [Related]
15. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
Goldfischer ER; Breaux J; Katz M; Kaufman J; Smith WB; Kimura T; Sand M; Pyke R
J Sex Med; 2011 Nov; 8(11):3160-72. PubMed ID: 21933348
[TBL] [Abstract][Full Text] [Related]
16. Correlation of question 15 of the FSDS-DAO with clinician evaluation of female orgasmic disorder.
Dickstein JB; Goldstein SW; Tkachenko N; Kreppner W
J Sex Med; 2013 Sep; 10(9):2251-4. PubMed ID: 23782579
[TBL] [Abstract][Full Text] [Related]
17. Androgens and Psychosocial Factors Related to Sexual Dysfunctions in Premenopausal Women
Wåhlin-Jacobsen S; Kristensen E; Pedersen AT; Laessøe NC; Cohen AS; Hougaard DM; Lundqvist M; Giraldi A
J Sex Med; 2017 Mar; 14(3):366-379. PubMed ID: 28117267
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review on Mindfulness Meditation-Based Interventions for Sexual Dysfunctions.
Jaderek I; Lew-Starowicz M
J Sex Med; 2019 Oct; 16(10):1581-1596. PubMed ID: 31570137
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
Thorp J; Simon J; Dattani D; Taylor L; Kimura T; Garcia M; Lesko L; Pyke R;
J Sex Med; 2012 Mar; 9(3):793-804. PubMed ID: 22239862
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis.
Gao Z; Yang D; Yu L; Cui Y
J Sex Med; 2015 Nov; 12(11):2095-104. PubMed ID: 26745616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
